UB 165 fumarate

Subunit selective nAChR agonist CAS# 200432-86-6

UB 165 fumarate

Catalog No. BCC5746----Order now to get a substantial discount!

Product Name & Size Price Stock
UB 165 fumarate: 5mg $161 In Stock
UB 165 fumarate: 10mg Please Inquire In Stock
UB 165 fumarate: 20mg Please Inquire Please Inquire
UB 165 fumarate: 50mg Please Inquire Please Inquire
UB 165 fumarate: 100mg Please Inquire Please Inquire
UB 165 fumarate: 200mg Please Inquire Please Inquire
UB 165 fumarate: 500mg Please Inquire Please Inquire
UB 165 fumarate: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of UB 165 fumarate

Number of papers citing our products

Chemical structure

UB 165 fumarate

3D structure

Chemical Properties of UB 165 fumarate

Cas No. 200432-86-6 SDF Download SDF
PubChem ID 71297058 Appearance Powder
Formula C17H19ClN2O4 M.Wt 350.8
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in water with gentle warming
Chemical Name (E)-but-2-enedioic acid;2-(6-chloropyridin-3-yl)-9-azabicyclo[4.2.1]non-2-ene
SMILES C1CC2CCC(N2)C(=C1)C3=CN=C(C=C3)Cl.C(=CC(=O)O)C(=O)O
Standard InChIKey DZFRKSLRKAKJIB-WLHGVMLRSA-N
Standard InChI InChI=1S/C13H15ClN2.C4H4O4/c14-13-7-4-9(8-15-13)11-3-1-2-10-5-6-12(11)16-10;5-3(6)1-2-4(7)8/h3-4,7-8,10,12,16H,1-2,5-6H2;1-2H,(H,5,6)(H,7,8)/b;2-1+
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of UB 165 fumarate

DescriptionSubtype-selective nicotinic agonist. Full agonist at α3β2- and very weak partial agonist at α4β2- containing nAChRs. Ki values are 0.27, 20 (IC50), 2790 and 990 nM for α4β2, α3, α7 and α1β1δε respectively.

UB 165 fumarate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

UB 165 fumarate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of UB 165 fumarate

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.8506 mL 14.2531 mL 28.5063 mL 57.0125 mL 71.2657 mL
5 mM 0.5701 mL 2.8506 mL 5.7013 mL 11.4025 mL 14.2531 mL
10 mM 0.2851 mL 1.4253 mL 2.8506 mL 5.7013 mL 7.1266 mL
50 mM 0.057 mL 0.2851 mL 0.5701 mL 1.1403 mL 1.4253 mL
100 mM 0.0285 mL 0.1425 mL 0.2851 mL 0.5701 mL 0.7127 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on UB 165 fumarate

Different nicotinic acetylcholine receptor subtypes mediating striatal and prefrontal cortical [3H]dopamine release.[Pubmed:15617729]

Neuropharmacology. 2005 Jan;48(1):72-9.

Different nicotinic acetylcholine receptor subtypes appear to modulate dopamine release from the striatum and prefrontal cortex. In this study a combination of subtype-selective antagonists and agonists were used to extensively characterize the nAChRs involved in dopamine release from slice preparations of these two brain regions. alpha-conotoxin-MII inhibited nicotine-evoked [3H]dopamine (DA) release from striatum by 45%, but did not affect cortical dopamine release. Neither methyllycaconitine, alpha-bungarotoxin, nor alpha-conotoxin-ImI affected nicotine-evoked [3H]DA release from either striatum or prefrontal cortex. MG 624, a novel selective nAChR antagonist, inhibited cortical [3H]DA by 53%, but had no effect on striatal release. Compared to nicotine, (+/-)-UB-165 showed less efficacy with respect to dopamine release from striatum, and had no effect on cortical dopamine release. (+/-)-UB-165-evoked striatal dopamine release was completely blocked by mecamylamine, partially blocked (up to 55%) by alpha-conotoxin-MII, and unaffected by methyllycaconitine or alpha-conotoxin-ImI. alpha4beta2* and alpha6beta2beta3* nAChRs appear to play a role in striatal dopamine release, whereas alpha4beta2* nAChRs modulate release from prefrontal cortex. alpha7* nAChRs do not appear to play a role in nAChR-mediated dopamine release from either brain region.

UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes.[Pubmed:10751429]

J Neurosci. 2000 Apr 15;20(8):2783-91.

Presynaptic nicotinic acetylcholine receptors (nAChRs) on striatal synaptosomes stimulate dopamine release. Partial inhibition by the alpha3beta2-selective alpha-conotoxin-MII indicates heterogeneity of presynaptic nAChRs on dopamine terminals. We have used this alpha-conotoxin and UB-165, a novel hybrid of epibatidine and anatoxin-a, to address the hypothesis that the alpha-conotoxin-MII-insensitive subtype is composed of alpha4 and beta2 subunits. UB-165 shows intermediate potency, compared with the parent molecules, at alpha4beta2* and alpha3-containing binding sites, and resembles epibatidine in its high discrimination of these sites over alpha7-type and muscle binding sites. (+/-)-Epibatidine, (+/-)-anatoxin-a, and (+/-)-UB-165 stimulated [(3)H]-dopamine release from striatal synaptosomes with EC(50) values of 2.4, 134, and 88 nM, and relative efficacies of 1:0.4:0.2, respectively. alpha-Conotoxin-MII inhibited release evoked by these agonists by 48, 56, and 88%, respectively, suggesting that (+/-)-UB-165 is a very poor agonist at the alpha-conotoxin-MII-insensitive nAChR subtype. In assays of (86)Rb(+) efflux from thalamic synaptosomes, a model of an alpha4beta2* nAChR response, (+/-)-UB-165 was a very weak partial agonist; the low efficacy of (+/-)-UB-165 at alpha4beta2 nAChR was confirmed in Xenopus oocytes expressing various combinations of human nAChR subunits. In contrast, (+/-)-UB-165 and (+/-)-anatoxin-a were similarly efficacious and similarly sensitive to alpha-conotoxin-MII in increasing intracellular Ca(2+) in SH-SY5Y cells, a functional assay for native alpha3-containing nAChR. These data support the involvement of alpha4beta2* nAChR in the presynaptic modulation of striatal dopamine release and illustrate the utility of exploiting a novel partial agonist, together with a selective antagonist, to dissect the functional roles of nAChR subtypes in the brain.

Keywords:

UB 165 fumarate,200432-86-6,Natural Products,Nicotinic Receptor, buy UB 165 fumarate , UB 165 fumarate supplier , purchase UB 165 fumarate , UB 165 fumarate cost , UB 165 fumarate manufacturer , order UB 165 fumarate , high purity UB 165 fumarate

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: